Kornimate/medical-research-clean huggingface dataset:
self-help app and wellbeing

Conditions: Anxiety and Worry

Summary: anxiety and worry are amongst the most common mental health difficulties. the second mental health study found a significant increase in the lifetime prevalence for gad, from 0.9% to 1.6%. in addition, the organisation for economic cooperation and development found that among singaporean students, 86% experienced anxiety levels that were significantly higher than the oecd average. past research revealed that individuals who worried more experienced decreases in life satisfaction. it was also found that worry and anxiety are significant predictors of one's psychological wellbeing . in line with this trend, the market for wellbeing apps have been one of the fastest growing categories of apps ever since; with more than 10,000 on the market. studies have shown that the use of wellbeing apps has been correlated with an improvement in mental wellbeing. however, due to the lack of research that focuses on disorder-specific evidence, there still exists debates around the effectiveness of wellbeing apps on anxiety and worry. in addition, the lack of research on the mediating factor of psychological mindedness in the relationship between the use of wellbeing apps and mental well-being, could be pivotal to the effectiveness of wellbeing apps. to show the effectiveness of evidence-based wellbeing apps in targeting anxiety and worry, this study will employ the engagement of participants with a wellbeing app for a controlled period of 2 weeks before recording their mental wellbeing outcomes.this paradigm has been replicated extensively through multiple studies. this study will use a between-groups experimental study design whereby participants will be block randomised into 2 conditions: active control condition, and anxiety condition. each condition will be given a restricted version of the wellbeing app according to their treatment groups. follow-up data will be collected at 2-weeks post intervention to establish efficacy of the intervention. objective 1: to evaluate the effectiveness of a wellbeing app self-help programme for reducing anxiety and worry. objective 2: to examine if psychological mindedness moderates hypothesised effects of wellbeing app usage and anxiety and worry. hypothesis 1: participants in the intervention group will report significantly lower anxiety and worry than participants in the control group. hypothesis 2: psychological mindedness will moderate the effect of the wellbeing app's self-help programme on anxiety and worry: participants high in psychological mindedness will benefit more from the wellbeing apps than those with lower scores on psychological mindedness.


Eligibility criteria:
inclusion criteria: * at least 18 years old for nus students, or 21 for non nus students exclusion criteria: * participants who do not meet the age requirement

Keywords: self-help app wellbeing experimental
efficacy confirmation study of cdp870 in early rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of this study is to assess the efficacy of certolizumab pegol (czp) with methotrexate (mtx) compared with mtx-alone in patients with early-stage rheumatoid arthritis (ra) who are naive to mtx and have with poor prognostic factors, using inhibition of radiographically confirmed joint damage progression over a one-year period as a primary endpoint. following a year of treatment with czp plus mtx treatment, czp will be discontinued, and the subjects will be monitored for one more year (the follow-up period) to investigate the sustainability of efficacy of czp during the mtx monotherapy for exploratory purposes.

this study was initiated by otsuka pharmaceutical co., ltd and transferred to astellas on 12/04/2012.

Eligibility criteria:
inclusion criteria: * subjects with ra as defined by the acr/eular criteria (2010) who meet all of the following criteria: 1. subjects who developed ra within one year after onset of ra. 2. subjects who have never received mtx before (mtx naive) 3. subjects whose disease activity is moderate or higher (das28(esr) ≥ 3.2） 4. subjects must satisfy at least two of the three criteria (anti-ccp antibody positive, rheumatoid factor positive, presence of x-ray erosion） for poor prognostic factors. the anti-ccp antibody positive is essential for every patient. exclusion criteria: * patients who have a diagnosis of any other type of inflammatory arthritis. * patients who have a secondary, non-inflammatory type of arthritis. * patients who have used with mtx, reflunomide, or any other biologics prior to the start of study drug administration. * patients who have nyha (new york heart association) class iii or iv congestive heart failure * patients who currently have, or who have a history of, tuberculosis. * patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease) * patients who currently have, or have a history of, malignant tumor * female patients who are breastfeeding or pregnant, who are of childbearing potential

Keywords: cimzia early ra certolizumab pegol
biglobal intervention study: improving diagnosis and management of suspected brain infections globally

Conditions: Meningitis; Encephalitis; Abscess Brain

Summary: background: patients with suspected brain infections pose major challenges to low and middle income countries, including their disproportionately high burden, diverse causes with inadequate surveillance, requirement for invasive and expensive tests, and the difficulty of management without a clear diagnosis. this is all compounded by resource and system constraints. few studies have attempted to improve the care of these people in resource-limited settings. aim: this study sets out to improve the diagnosis and early management of people with suspected acute (\<28 days of symptoms) brain infections in low and middle income countries, using a coordinated thematic approach. outcomes: the primary outcome will be proportion of people with suspected acute brain infection receiving a diagnosis. secondary outcomes will include mortality, length of stay in hospital, quality of life, degree of disability, and proportion having a lumbar puncture test. participants: children and adults with features consistent with an acute brain infection, including meningitis and encephalitis, will be recruited at a variety of hospitals in brazil, india and malawi. study procedures: an assessment of current practice and capabilities at each hospital, including patient and sample journey observations and interviews with healthcare staff, will identify barriers to optimal care. using this, a sustainable pragmatic multi-component intervention will be produced, with components modifiable to each hospital's needs. outcomes will be reassessed post-intervention.


Eligibility criteria:
inclusion criteria: 1. adults, infants and children presenting to a study hospital with symptoms and/or signs suggestive of acute brain infection, which could be suspected encephalitis, suspected meningitis, or alternative features raising suspicion of brain infection. 2. symptom duration of less than 4 weeks. exclusion criteria: 1. neonates, i.e. children under the age of 28 days. 2. people with pre-existing indwelling ventricular devices (e.g. extra-ventricular drains, ventriculo-peritoneal shunts) or other implants in contact with the meninges or brain (e.g. deep brain stimulators). 3. people without an indwelling device, having undergone neurosurgical procedures within the preceding 12 months.
nash in subjects with different classes of obesity

Conditions: NASH - Nonalcoholic Steatohepatitis; NAFLD; Obesity; Obesity, Morbid

Summary: it is an observational trial on 500 subjects. the purpose of this trial is to assess the prevalence of non-alcoholic steatohepatitis (nash) in subjects with different classes of obesity.

nonalcoholic fatty liver disease (nafld) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. the development of nash leads to an increase in morbidity and mortality. since patients with obesity are at an increased risk of nash, the aim of this trial is to assess the prevalence of nash in this class of patients.

Eligibility criteria:
inclusion criteria: * aged between 19 and 69 years exclusion criteria: * pregnancy * active cancer * end stage renal failure * end stage liver failure * being unable to understand and sign informed consent
to translate and validate the topas toronto psoriatic screening questionnaire)into spanish

Conditions: Psoriatic Arthritis

Summary: to transalete and validate de toronto psoriatic arthritis secreening questionaire into spanish

this is part of the colombian registry of patients with psoriasis and psoriatic arthritis

Eligibility criteria:
inclusion criteria: * adult with psoriasis in the dermatology clinic exclusion criteria: * adult with other autoimmune disease
reproducibility of functional shoulder tests for the return to sport of patients operated on previous shoulder instability

Conditions: Latarjet; Shoulder Injuries

Summary: the aim of this study is to assess whether the indicators outcome of these tests discriminate between different populations. in particular to compare populations with shoulders without any history of injury with a population that had undergone a reduction in glenohumeral instability by the latarjet technique.

the different objectives of this study are : * to assess the intra- and intersessional reproducibility of functional shoulder tests * to evaluate the influence of an anterior front stop using the latarjet method on the functional profile of the shoulder compared to a healthy population.

Eligibility criteria:
inclusion criteria: patient group : * male patient * between 18 and 30 years-old * occurrence of the injury requiring surgery during a sports activity * reduction of shoulder instability by the latarjet technique * surgery performed by surgeon from santy orthopedic center (lyon) * patient's inclusion by decision of the surgeon during the 4 months postoperatively visit healthy volunteer group : * male patient * between 18 and 30 years-old * patient regularly practicing sport activity. both groups : * patient having signed an informed consent * affiliated subject or beneficiary of a social security scheme exclusion criteria: patient group : * contra indication from surgeon * having another pathology in the upper limbs * present a constitutional hyperlaxity * have stiffness or recurrence of dislocation of the shoulder post-surgery healthy volunteer group : * report a history of upper extremity pain / injury within the past 12 months * report a history of orthopedic surgery on the upper limbs all participants : * protected subject : adult under guardianship, guardianship or other legal protection, deprived of liberty by judicial or administrative decision * pregnant woman, breastfeeding, parturient
implementation of 23 hour surgery model in a tertiary hospital

Conditions: Ambulatory Surgery; Laparoscopy; Shoulder Impingement Syndrome; Ovarian Cysts; Cholecystolithiasis; Appendicitis; Gynecologic Surgical Procedures; Ambulatory Surgical Procedures; Neurosurgery

Summary: extended day surgery or 23 h surgery (23-hour surgery) is a surgical model where patients arrive to the hospital from home at the day of surgery, are operated and recover in a 23 h surgery unit. 23h surgery units are usually situated near postoperative recovery unit. the 23 h surgical model was implemented in kuopio university hospital 2015 and between may 2017-may 2018 patients were recruited in the present prospective follow up cohort study. patients were informed and they gave their informed consent. the patients were contacted two weeks after the study and details of their recovery were asked.

extended day surgery or 23 h surgery is a surgical model where patients arrive to the hospital from home at the day of surgery, are operated and recover in a 23 h surgery unit. 23h surgery units are usually situated near postoperative recovery unit. the 23 h surgical model was implemented in kuopio university hospital 2015 and between may 2017-may 2018 patients were recruited in the present prospective follow up cohort study. patients were informed and they gave their informed consent. the patients were contacted two weeks after the study and details of their recovery were asked. satisfaction to the care in 23 h unit and surgical process, were asked. amount of readmissions, reoperations, contacts to health care professionals and adverse events are recorded. detailed information about intensity of pain, analgesic need and use in the hospital was recorded and pain interference in daily life for short term recovery period was asked.

Eligibility criteria:
inclusion criteria: * adult * gave informed consent exclusion criteria: * no informed consent

Keywords: 23 h surgery postoperative recovery outcome patient satisfaction postoperative pain analgesic oxycodone multimodal pain management extended day surgery
national, multicenter, retrospective, prospective study to evaluate pediatric gastrointestinal eosinophilic disorders

Conditions: Eosinophilic Gastrointestinal Disorders; Eosinophilic Esophagitis; Eosinophilic Gastritis or Gastroenteritis; Eosinophilic Colitis

Summary: eosinophilic gastrointestinal disorders (egids) are a heterogeneous group of emerging chronic inflammatory diseases that may affect different gastrointestinal (gi) tracts. based on the anatomical site involved, egids are distinguished into eosinophilic esophagitis (eoe) and non-esophageal forms, which are subdivided into eosinophilic gastritis (eog), gastroenteritis (eoge), and colitis (eoc). eoe is considered the prototype of egids. since the first description of a case series of patients with eoe, fundamental scientific advances have been achieved, culminating in the redaction of international diagnostic and therapeutic guidelines. in contrast to eoe, non-esophageal forms of egids are still a clinical enigma with evidence limited to a few retrospective studies. in the last decade, an increase in the prevalence of egids has been observed in the pediatric age. unfortunately, the epidemiology of egids in italy is still inconsistent and clear estimates are not available. firstly, this study will allow us to assess and clarify several clinical and epidemiological aspects of pediatric egids, in particular: 1. prevalence and incidence of pediatric egids in italy, 2. the clinical features and potential phenotypes of pediatric egids with potential impact on therapy and management, 3. diagnostic work-up and adherence to the eoe international guidelines to improve the management, quality of care, and quality of life of affected patients. this study has no ethical problems since eoe patients are treated according to international guidelines and those with non-esophageal egids according to the latest scientific evidence.


Eligibility criteria:
inclusion criteria: - all egids patients aged 0-18 years and followed at the centers involved in the study will be considered eligible. informed consent must be obtained from each enrolled patient and signed by a parent/legal guardian and patient (when older than six years). exclusion criteria: - this study will not include patients with: 1. a diagnosis of egids made more than five years before the study participation; 2. a diagnosis of eoe not in line with current international guidelines; 3. a secondary cause of intestinal eosinophilic inflammation (inflammatory bowel diseases, autoimmune diseases, vasculitis, graft versus host disease, malignancies).

Keywords: eosinophilic gastrointestinal disorders children prevalence incidence
quality of life for pediatric urolithiasis

Conditions: Pediatric ALL

Summary: the aim of this study is to assess the quality of life (qol) in pediatric patients with urinary stone disease.

this study will assess the quality of life (qol) in pediatric patients with urinary stone disease using the pediatric quality of life (pedsqol) questionnaire in comparison to normal healthy age/sex matched population.

Eligibility criteria:
inclusion criteria: * patients who had urinary stones exclusion criteria: 1. patients presenting with obstructive uropathy or urosepsis. 2. recent (less than 4 weeks) surgical intervention for urinary stone disease. 3. indwelling urinary catheters or stents (urethral catheter, ureteral stents or nephrostomy tube). 4. associated mental illness or cognitive dysfunction. 5. associated chronic medical illness that may compromise qol.

Keywords: urolithiasis quality of life pcnl swl
the safety and efficacy of embotrap in treating acute ischemic stroke patients

Conditions: Stroke; Acute Ischemic Stroke

Summary: this is a prospective, multicenter, cohort study aiming to compare the safety and efficacy of embotrap stent retriever to other stent retrievers without inner channel for acute middle cerebral artery occlusion (mcao). all enrolled patients will be followed up at 90 days after randomization.

ais due to large vessel occlusion (lvo) remains a substantial cause of mortality and morbidity. recent guidelines have recommended mt as the first-line therapy for ais-lvo in the anterior circulation. thrombectomy using a stent retriever is safe and effective in the treatment of ais. as a new generation of stent retriever, embotrap stent retriever has a unique design including an open outer cage for clot capture and a closed inner channel for clot stabilization. previous studies showed embotrap stent retriever can achieve a successful recanalization of 88% and favorable outcome of 51%. also, the multicenter arise ii study showed the first-pass effect of embotrap stent retriever was 40.1%, higher than other stent retrievers, such as solitaire fr and trevo device. but most studies were single-armed without direct comparison. thus, this prospective cohort study is designed to compare the safety and efficacy of embotrap stent retriever with other stent retrievers without inner channel.

Eligibility criteria:
inclusion criteria: 1. subjects with symptoms due to acute middle cerebral artery occlusion (mcao) treated with mt with or without intravenous thrombolysis. 2. premorbid mrs 0-2 3. ages 18-80 years 4. nihss ≥6 at admission 5. the time from onset to groin puncture ≤ 24 hours 6. aspects 6-10 on non-contrast ct (ncct) scan, mri or ct-perfusion (ctp) 7. informed consent approved by patients or acceptable patient surrogate. exclusion criteria: 1. any intracranial hemorrhage or severe cerebral infarction on ct or mri (aspects \ 1/3 middle cerebral artery territory). 2. severe allergy to contrast media allergy and nitinol 3. refractory hypertension (sbp \> 185 mmhg or dbp \> 110 mmhg) 4. platelet count \< 30 x 10\^9 / l 5. coagulopathy history or hemorrhage disorders disease 6. concurrent participation in a study involving an investigational drug or device that would impact the current study 7. evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy 8. unable to complete the study and follow-up due to mental disorders, cognitive or emotional disorders 9. pregnant or lactating women 10. anticipated life expectancy \< 6 months 11. patients without a legally authorized representative to sign the consent form 12. for other reasons, the researchers believe that the patient is not suitable for enrollment

Keywords: embotrap acute ischemic stroke mechanical thrombectomy stent retriever
cmv infection and immune intervention after transplantation

Conditions: CMV Viremia; Transplantation Infection

Summary: allogeneic hematopoietic stem cell transplantation (allo-hsct) is an effective or even the only way to cure blood malignant diseases. cytomegalovirus (cmv) infection is a serious early complication of allo-hsct. its high incidence and poor prognosis can cause a series of terminal organ diseases such as cmv pneumonia, encephalitis, and enteritis,which seriously affecting the prognosis of patients post allo-hsct. our data show that rapid reconstruction of nk cells after transplantation can reduce the incidence of cmv infection. patients with a rapid reconstruction of nkg2c after transplantation have a low cmv infection rate, and patients with strong secretion of ifn-gamma of nk after transplantation have low cmv infection. our previous research showed that trophoblast cells transfected with il-21 and 4-1bbl can achieve a large number of clinical-grade expansion of nk cells (mil-21 / 4-1bbl nk cells), and mil-21 / 4-1bbl nk cells it is safe to treat patients with minimal residual disease (mrd) positive aml after transplantation, and can induce mrd to turn negative. previous studies have shown that adoptive infusion of expanded nk cells after haplotype transplantation is safe and can improve the functional reconstruction of nk cells. therefore, we hypothesized that the infusion of nk cells can improve the antiviral capacity of nk cells, thereby effectively reducing the cmv infection. incidence.


Eligibility criteria:
inclusion criteria: 1. patients with acute leukemia (al) or myelodysplastic syndrome (mds) or myeloma or lymphoma undergoing haploidentical allogeneic stem cell transplantation 2. no cmv infection by 20 days ± 3 days after transplantation 3. no active acute gvhd by 20 days ± 3 days after transplantation 4. the dose of prednisolone was less than 0.5mg / kg / d within 72 hours before and after infusion of nk cells 5. prior to transplantation, the cmv igg of the recipient and donor were positive, and the recipient had a suitable donor to expand nk cells. 6. patient age 16-65 years 7. donor age 16-65 years 8. patient karnofsky score\> 70% 9. estimated survival\> 3 weeks 10. patient agrees to participate in study exclusion criteria: 1. participants in any other clinical trials within 1 month before enrollment 2. active infection 3. hbv or hcv or hiv carriers 4. with moderate to severe renal dysfunction (blood creatinine\> 130umol / l) and / or liver dysfunction (total bilirubin\> 34umol / l, alt, ast\> 2 times the upper limit of normal) before nk infusion 5. researchers do not consider it appropriate to participate in this trial.